93. Primary biliary cholangitis Clinical trials / Disease details

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05751967 (ClinicalTrials.gov)	February 22, 2023	13/12/2022	Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis	A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid	Primary Biliary Cholangitis	Drug: Placebo Combined With Ursodeoxycholic Acid;Drug: Fenofibrate Combined With Ursodeoxycholic Acid	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	150	Phase 3	China
2	NCT05749822 (ClinicalTrials.gov)	February 17, 2023	29/12/2022	Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis	Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid	Primary Biliary Cholangitis	Drug: Fenofibrate 200mg;Drug: Placebo;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	104	Phase 2/Phase 3	China
3	ChiCTR1800020160	2018-12-20	2018-12-18	Clinical research for fenofibrate in the treatment of refractory primary biliary cirrhosis	Clinical research for fenofibrate in the treatment of refractory primary biliary cirrhosis	Primary Biliary Cirrhosis	1:Fenofibrate+UDCA;2:UDCA;	Peking Union Medical College Hosipital	NULL	Recruiting	18	65	Both	1:20;2:20;		China
4	NCT02823353 (ClinicalTrials.gov)	April 8, 2016	28/1/2016	Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis	Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control Study	Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Completed	18 Years	70 Years	All	117	Phase 3	China
5	NCT02965911 (ClinicalTrials.gov)	January 2016	15/11/2016	Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA	A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA	Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Beijing 302 Hospital	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 1/Phase 2	China
6	NCT02823366 (ClinicalTrials.gov)	January 2016	28/1/2016	Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid		Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	70 Years	All	104	Phase 3	China
7	NCT01141296 (ClinicalTrials.gov)	April 2011	8/6/2010	Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis	Randomized Controlled Study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis	Primary Biliary Cirrhosis	Drug: fenofibrate;Drug: placebo	University of Miami	Mayo Clinic	Withdrawn	21 Years	75 Years	Both	0	Phase 2	United States
8	NCT00575042 (ClinicalTrials.gov)	August 2007	13/12/2007	Use of Fenofibrate for Primary Biliary Cirrhosis	Pilot Study of Fenofibrate for Primary Biliary Cirrhosis	Primary Biliary Cirrhosis	Drug: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	University of Florida	The PBCers Organization;Shionogi Inc.	Completed	21 Years	75 Years	All	20	Phase 2	United States